Abstract:Innate immune response provides the host with an early protection barrier against invading pathogens and helps shape the nature and quality of the subsequent adaptive immune response of the host. Ubiquitin-specific protease 18 (USP18 ) plays an important role in the host innate immune response. This role is mediated both via its enzymatic and non-enzymatic functions. First, conjugation of ISG15 to its targets is counteracted by the enzymatic activity of USP18. Second, the C terminus of USP18 can bind to the type I interferon receptor subunit (IFNAR2) and compete with JAK1 receptor binding which inhibits the activation of the receptor associated kinases JAK1 and TYK2. While USP18 deficiency prolonged phosphorylation of STATs and increased ISG expression in response to IFN, forced expression of either wild type or enzymatically inactive mutatant USP18 in the cells reduces the phosphorylation level of STATs and the downstream transcriptional events. USP18 knockout mice have a greater resistance to viral/bacterial infection in several experimental mouse models. In addition, USP18 was found to inhibit IFNsignaling but did not inhibit IFN, IFN, IL-6, or IL-12 signaling pathways. Results from our previous study demonstrated that USP18 was overexpressed in the liver biopsy specimens of HCV patients who do not respond to the combination therapy of pegylated interferon-alpha (IFN) and ribavirin (RBV). We also found that increased expression of either wild type USP18 or catalytically inactive mutant USP18 blunted the effect of both type I and type III IFNs and promoteded HCV production in the J6/JFH1 culture system. Another study suggested that HBV infection is more rapidly cleared if USP18 expression level is reduced. Most recently it has been shown that USP18 may play an important role in mediating inflammation. Inhibition of USP18 leads to upregulation of several pro-inflammatory chemokine, including CCL5, CXCL10 and IL-15, via induction of the STAT signaling pathway and increases IFN induced beta cell apoptosis. Taken together, small molecule inhibitors against USP18 might be a viable approach to potentiate the host innate immunity leading to a better control of viral infections.

USP22 Promotes IRF3 Nuclear Translocation and Antiviral Responses by Deubiquitinating the Importin Protein KPNA2

USP26 suppresses type I interferon signaling by targeting TRAF3 for deubiquitination

USP21 Negatively Regulates Antiviral Response by Acting As a RIG-I Deubiquitinase

USP18 recruits USP20 to promote innate antiviral response through deubiquitinating STING/MITA

Ubiquitin-specific Protease 15 Negatively Regulates Virus-induced Type I Interferon Signaling via Catalytically-dependent and -independent Mechanisms

USP3 Inhibits Type I Interferon Signaling by Deubiquitinating RIG-I-like Receptors

Deubiquitinase USP47 attenuates virus-induced type I interferon signaling

Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6

USP20 Promotes Cellular Antiviral Responses via Deconjugating K48-Linked Ubiquitination of MITA

Deubiquitinase USP2a Sustains Interferons Antiviral Activity by Restricting Ubiquitination of Activated STAT1 in the Nucleus

The Ubiquitin-Specific Protease 17 is Involved in Virus-Triggered Type I IFN Signaling

USP18 positively regulates innate antiviral immunity by promoting K63-linked polyubiquitination of MAVS

Usp4 Positively Regulates Rig-I-Mediated Antiviral Response Through Deubiquitination and Stabilization of Rig-I

Ubiquitin-Conjugating Enzyme 2S Enhances Viral Replication by Inhibiting Type I IFN Production through Recruiting USP15 to Deubiquitinate TBK1.

The role of USP 18 in interferon signaling and inflammation

USP1-UAF1 Deubiquitinase Complex Stabilizes TBK1 and Enhances Antiviral Responses

USP22 is a Positive Regulator of NFATc2 on Promoting IL2 Expression.

Ubiquitin-specific proteases 25 negatively regulates virus-induced type I interferon signaling.

Usp19 Modulates Autophagy and Antiviral Immune Responses by Deubiquitinating Beclin-1

USP13 negatively regulates antiviral responses by deubiquitinating STING

USP2a negatively regulates IL-1β- and virus-induced NF-κB activation by deubiquitinating TRAF6.